Chemical inhibitors of Smok3a target various signaling pathways and enzymes that are involved in its activation or function. Wortmannin and LY294002 are both phosphoinositide 3-kinase (PI3K) inhibitors that can impede the phosphorylation of downstream targets crucial for Smok3a activity. This can result in a blockade of the PI3K/Akt pathway, a known mediator of various cellular functions, which is likely to be involved in the activation and function of Smok3a. Similarly, PD98059 and U0126 can inhibit the MEK/ERK pathway, where MEK1 and MEK2 are upstream regulators of ERK. This inhibition can disrupt the MEK/ERK signaling cascade, potentially reducing the phosphorylation and subsequent activation of Smok3a. Additionally, SP600125, as a c-Jun N-terminal kinase (JNK) inhibitor, can prevent the JNK signaling pathways from activating Smok3a. SB203580 specifically inhibits p38 MAP kinase and can hinder the p38 MAPK-mediated signaling pathways that may contribute to Smok3a's activity.
Furthermore, rapamycin can inhibit the mechanistic target of rapamycin (mTOR), which plays a pivotal role in cell growth and proliferation. This inhibition can decrease the phosphorylation of targets that could be essential for Smok3a's functional state. Dasatinib and PP2, both Src family kinase inhibitors, can obstruct the Src kinase-mediated signaling that might be integral for Smok3a's activation. Y-27632, by selectively inhibiting Rho-associated protein kinase (ROCK), can interfere with ROCK-dependent signaling pathways, which may affect Smok3a's activity. ZM-447439 targets Aurora kinases, whose inhibition can disrupt the phosphorylation of substrates required for Smok3a activation. Lastly, BIX 02189, as a selective inhibitor of MEK5, can inhibit the MEK5/ERK5 pathway, potentially reducing the activation of Smok3a if it relies on ERK5-mediated signaling for its function. Each inhibitor targets specific enzymes or pathways to disrupt the signaling cascade that contributes to the activation and function of Smok3a, leading to its functional inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which can inhibit Smok3a by preventing the phosphorylation of downstream targets that may be critical for Smok3a activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, which can inhibit Smok3a by blocking the PI3K/Akt pathway, thereby hindering any potential Akt-mediated phosphorylation that might activate Smok3a. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which works upstream of ERK. As ERK can be involved in the activation of various proteins, the inhibition of MEK, and therefore ERK, can reduce the activation of Smok3a if it is ERK-dependent. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2, which may inhibit Smok3a by blocking the MEK/ERK pathway, potentially reducing the phosphorylation and activation of Smok3a. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which could inhibit Smok3a by blocking JNK signaling pathways that might be responsible for Smok3a activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, which could inhibit Smok3a by hindering p38 MAPK-mediated signaling pathways that may play a role in the activation or function of Smok3a. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is a key regulator of cell growth and proliferation. By inhibiting mTOR, rapamycin may reduce the phosphorylation of targets that are important for Smok3a function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor, which could inhibit Smok3a by blocking the activity of Src family kinases that may be involved in pathways activating Smok3a. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is another Src family kinase inhibitor, which may inhibit Smok3a by preventing Src kinase-mediated signaling that could be essential for Smok3a activation or function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of the Rho-associated protein kinase (ROCK), which could inhibit Smok3a by inhibiting ROCK-dependent signaling pathways that may influence Smok3a activity. | ||||||